Pharmacy Times

AUGUST 18, 2022

Analysis is based on functional magnetic resonance imaging to provide insight into the effective connectivity.

181

181

PharmaVoice

AUGUST 18, 2022

Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.

105

105

Pharmacy Times

AUGUST 18, 2022

Adalimumab-bwwd is a tumor necrosis factor blocker indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis.

FDA 123

FDA 123

Pharmaceutical Technology

AUGUST 18, 2022

Atomwise and Sanofi have entered a strategic and exclusive research partnership to use the former’s artificial intelligence (AI)-driven AtomNet platform to discover and research up to five drug targets computationally. The approach of Atomwise makes the process of drug discovery more logical and efficient by moving away from serendipitous discovery and toward a search that is structure-based.

Compounding 98

Compounding 98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

AUGUST 18, 2022

In a recent survey, community pharmacists discussed current hardships in the industry, which include low supply, increasing costs, and trouble filling necessary positions.

123

123

pharmaphorum

AUGUST 18, 2022

Endo International is the latest drugmaker to file for chapter 11 bankruptcy protection in connection with opioid litigation in the US, after agreeing a $6 billion deal with creditors that includes an offer to settle outstanding lawsuits. The Ireland-domiciled company is struggling under the weight of around $8 billion in debt, and has been hamstrung by costs associated with fighting thousands of suits that accuse it of wrongdoing in its marketing and promotion of painkiller Opana ER (oxymorphon

Documentation 108

Documentation 108

PharmExec

AUGUST 18, 2022

Richard Young, Vice President of Strategy, Vault CDMS and Tim Davis, Vice President of Strategy, MyVeeva for Patients, discuss the future of digital trials and their impact in the industry.

90

90

Pharmacy Times

AUGUST 18, 2022

The U.S. Health System can be difficult to navigate and creates barriers, which is why speaking up as health care professionals is extremely important.

123

123

European Pharmaceutical Review

AUGUST 18, 2022

Merck (MSD outside of the US and Canada) has entered into a collaboration agreement with Orna Therapeutics to discover, develop and commercialise multiple programmes of engineered circular RNA (oRNA) therapies, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the agreement, Merck will make an upfront payment to Orna of $150 million.

Research Laboratories 88

Research Laboratories Vaccines Packaging 88

Pharmacy Times

AUGUST 18, 2022

Dr. Christina Madison, The Public Health Pharmacist, was recently on Good Morning America discussing the do's and don'ts of expired medications.

123

123

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

AUGUST 18, 2022

As Frontiers Health approaches, we’re featuring interviews with members of the steering committee to give you a sneak peek of what to expect in Milan. Interested in signing up? pharmaphorum readers get a discount through this link. Though the field is still young, digital therapeutics are no longer a brand-new technology. Many different DTx offerings are in the field, being used by patients and prescribed by physicians, backed by rigorous scientific evidence.

98

98

Pharmacy Times

AUGUST 18, 2022

Investigators find that establishing immunity in the mucosal areas establishes a frontline defense against these diseases.

Immunization 123

Immunization Vaccines 123

NICE

AUGUST 18, 2022

Over the last 12 months, NICE has been working with the Care Quality Commission, Health Research Authority and Medicines and Healthcare products Regulatory Agency to develop a multi-agency advisory service for artificial intelligence (AI) and digital technologies in health and care (MAAS). Expected to launch next year, the MAAS will enable the development and widespread adoption of value-adding technologies, optimising care and improving outcomes across the health and care system.

81

81

Pharmacy Times

AUGUST 18, 2022

Investigators reported that people who frequently naps may have an increased risk of high blood pressure and ischemic stroke by 12% compared to people who do not nap.

123

123

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Outsourcing Pharma

AUGUST 18, 2022

The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies 59

Pharmacy Times

AUGUST 18, 2022

The drug also meets the key secondary endpoint of improved overall survival for treatment for individuals with HER2 positive unresectable and/or metastatic breast cancer.

65

65

pharmaphorum

AUGUST 18, 2022

Astellas remains on course to be the first drugmaker to bring a new non-hormonal therapy for symptoms of menopause to market, after the FDA started a review of its orally-active neurokinin-3 (NK3) receptor antagonist fezolinetant. The US regulator is scheduled to complete its review of fezolinetant as a treatment for moderate to severe vasomotor symptoms (VMS) of menopause, such as hot flushes and night sweats, by 22 February next year, said the Japanese pharma.

FDA 52

FDA 52

Pharmacy Times

AUGUST 18, 2022

For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel increased their rate of survival after 1 year by nearly 30%.

65

65

pharmaphorum

AUGUST 18, 2022

UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently-approved therapy for two forms of ANCA-associated vasculitis (AAV) – oral complement C5 inhibitor Tavneos – which will be launched in the next few weeks. CSL Vifor – which licenses Tavneos (avacopan) from US biotech ChemoCentryx – announced the decision on behalf Vifor Fresenius Medical Care Renal Pharma, its joint venture with Fresenius, which will market the drug in the UK.

Documentation 52

Documentation 52

Pharmacy Times

AUGUST 18, 2022

Each year, the NCPA Annual Convention is able to showcase student business plans in a competition that correlates to a real life business plan.

65

65

pharmaphorum

AUGUST 18, 2022

Researchers also dove into socio-economic disparities in cancer care. Last month in Chicago, Illinois the American Society of Clinical Oncology hosted its first in-person meeting since the COVID-19 pandemic began. In presentations and published abstracts, researchers shared a massive amount of data across all cancer types and treatment modalities. Below are just a few of the highlights from the show.

Chemotherapy 52

Chemotherapy Immunization 52

Pharmacy Times

AUGUST 18, 2022

Survey results reflect positive sentiments from older adults for the proposed Equitable Community Access to Pharmacist Services Act.

65

65

PharmExec

AUGUST 18, 2022

Raj Verma, chief diversity, culture, and experience officer at Sanofi, discusses the various ways people see diversity around the world and how companies should be building diversity, equity, and inclusion into a company’s everyday fabric.

52

52

Pharmacy Times

AUGUST 18, 2022

This month's product news includes women's wellness supplements, menstrual pain relief cream, and mineral sunscreen.

65

65

Pharmaceutical Technology

AUGUST 18, 2022

New Zealand’s Medsafe has granted expanded provisional approval for Novavax ’s protein-based Covid-19 vaccine Nuvaxovid (NVX-CoV2373) as a heterologous and homologous booster dose in adults aged 18 years and above. The booster vaccine is indicated for active immunisation for the prevention of Covid-19 in people of this age group. With the approval, people could opt to receive Nuvaxovid as their first and/or second booster dose(s) for Covid-19 following the conclusion of the initial vaccine re

Vaccines 52

Vaccines Immunization 52

Pharmacy Times

AUGUST 18, 2022

Ganciclovir injection is a nucleoside analogue cytomegalovirus DNA polymerase inhibitor.

73

73

pharmaphorum

AUGUST 18, 2022

bluebird bio’s Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA as a treatment for patients with beta thalassaemia who require regular blood transfusions. The US approval comes three years after Zynteglo (betibeglogene autotemcel) was approved for the same indication in Europe, and subsequently withdrawn after bluebird concluded that it wasn’t possible to build a commercially viable business for the gene therapy as the prici

FDA 52

FDA Insurance 52

Pharmacy Times

AUGUST 18, 2022

Study results show a compound annual growth rate of 5.2% from $392.4 billion in revenue in 2021.

Compounding 65

Compounding 65

PharmExec

AUGUST 18, 2022

There are several strategies life sciences companies can use to benefit from biosimilars.

52

52

Pharmacy Times

AUGUST 18, 2022

Uric Acid Cleanse helps to managing uric acid levels for kidney support.

65

65

Pharmaceutical Commerce

AUGUST 18, 2022

Company’s 344,000 square-foot facility revolves around pharma and medical items.

52

52

Pharma Times

AUGUST 18, 2022

Therapy for the treatment of myelofibrosis has received significant results from phase 3 trial

FDA 42

FDA 42

Pharmaceutical Commerce

AUGUST 18, 2022

Partnership adds technological offerings to PharmaLex’s repertoire.

52

52

Pharma Times

AUGUST 18, 2022

The SMC approval brings much-needed boost to asthma sufferers across Scotland

38

38